Mentioned in ?
References in periodicals archive ?
Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men.
Reply to alanine aminotransferase as an independent predictor of incident nonalcoholic fatty liver disease
Obesity is a key driver of nonalcoholic fatty liver disease and has also been identified as a risk factor for liver cancer.
Review: The role of insulin resistance in nonalcoholic fatty liver disease.
The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease.
Biopharmaceutical company Galmed Pharmaceuticals (NasdaqCM:GLMD) reported on Tuesday that it has received US Food and Drug Administration (FDA) approval for Investigational New Drug (IND) application for the ARRIVE Study to evaluate the safety and efficacy of Aramachol in patients with HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD).
At the moment there are no licensed medicines to treat nonalcoholic fatty liver disease, and so advice to patients at present is simply go on a diet.
Among associated complications, Nonalcoholic Fatty Liver Disease (NAFLD) is emerging as the most common chronic liver disease and is gaining increasing recognition as a component of the epidemic of obesity.
This is a significant development, as obesity-related conditions such as nonalcoholic fatty liver disease become key public health concerns on a global scale," commented Dr.
and Italy monitored the weight gain and development of nonalcoholic fatty liver disease and its progression to nonalcoholic steatohepatitis in MSG-treated mice fed either a calorie-restricted or regular diet.
The incidence of obesity is now at epidemic proportions and has resulted in the emergence of nonalcoholic fatty liver disease (NAFLD) as a common metabolic disorder that can lead to liver injury and cirrhosis.
The Virginia Commonwealth University School of Medicine (VCU) findings may provide researchers with potential new targets for treatment and also allow clinicians to further refine how they assess cardiovascular risk and develop ways to reduce it in individuals with a more aggressive form of nonalcoholic fatty liver disease called nonalcoholic steatohepatitis, or NASH.